TUC WEEKLY INTELLIGENCE BRIEF - September 28, 2026
THE UPLYFT COLLECTIVE
Weekly Intelligence Brief | Week of September 28, 2026
The Signal
This week, capital kept arriving in places most of the industry still treats as supporting infrastructure.
An Australian radiopharmaceutical company agreed to spend $1.65 billion on a manufacturer whose lead drug had just received an FDA rejection. A German pharmaceutical group moved closer to closing an $11.3 billion acquisition of a company that sells antibodies and reagents to laboratories. The Department of Veterans Affairs committed up to $775.72 million to two ambient documentation vendors after watching them operate inside its own hospitals for nearly a year. And a fertility brand raised $13 million after independent testing found it was one of only two prenatal products in a national review whose contents matched its label.
None of those buyers were primarily paying for discovery. They were paying for something further down the chain: manufacturing, supply, deployment, quality, and proof of execution.
Breakthrough science still creates enormous value, and one week does not make a trend. But when capital repeatedly shows up at the same point in the chain, it is worth asking whether the bottleneck has moved.
So the question to carry into next week is not what a company has invented. It is which link between that invention and a patient the company actually controls, and what happens to its margin if somebody else controls it.
What Smart Money Is Watching: who owns the links, because that is where this week’s money went.
The Capital Tape
1. What $1.65 billion buys when the FDA has just said no.
A few weeks before Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich for $1.65 billion, the FDA refused to approve ITM’s lead therapeutic asset. Most investors read a complete response letter as value destroyed. Telix appears to have reached the opposite conclusion. Telix and ITM
The FDA’s objections centered on chemistry, manufacturing and controls issues and findings from a third-party facility inspection. It raised no concerns about safety or efficacy. The Phase 3 COMPETE study had already shown superior progression-free survival against Novartis’s everolimus. BioSpace · STAT
That distinction is what Telix bought.
According to the merger announcement, ITM generated $273 million in revenue in 2025 and has grown at a 40% compound annual rate since 2021. The same document describes ITM as the world’s leading supplier of therapeutic radioisotopes and the only producer of globally scaled commercial-grade lutetium-177, characterizations that should be read as the parties’ framing. Even discounted, they point somewhere: the manufacturing that failed one inspection also supplies much of the field.
A regulator told a company its science was sound and its manufacturing was not. Within weeks, a buyer agreed to pay $1.65 billion for the business.
The market saw a regulatory setback. Telix saw infrastructure.
2. Merck KGaA clears the last hurdle on $11.3 billion of picks and shovels.
The largest life sciences transaction to advance this week was not for a drug, a platform, or a clinical asset. It was for the tools every drug developer uses.
Merck KGaA’s roughly $11.3 billion acquisition of Bio-Techne cleared shareholder approval on September 23 and is expected to close after final regulatory clearances. Bio-Techne sells the antibodies, proteins, reagents, analytical instruments and diagnostics that sit upstream of discovery itself, from 34 locations with more than 3,000 employees, on over $1.2 billion in fiscal 2025 revenue. Bio-Techne
Merck is not entering a new category. It already runs one of the largest life science tools and process-solutions businesses in the world, and Bio-Techne extends that position upstream into the earliest stages of research. The deal is less about expansion than about owning more of the workflow.
Every discovery program, including every AI-enabled one, ultimately consumes physical inputs. More computational discovery creates more laboratory validation, not less. The companies supplying those inputs participate in every success story without having to predict which program wins.
When everyone is prospecting, the dependable business is still selling shovels.
Decision question: in our category, what is the equivalent of the shovel, and who controls it?
3. Bird&Be raises $13 million, and the test results behind it deserve their own headline.
Consumer Reports tested 17 over-the-counter prenatal vitamins for label accuracy and heavy metals, publishing August 19 with a September 4 update. Only two matched their labels across every nutrient tested. One of them was the Bird&Be Complete Prenatal Pack. Consumer Reports
The finding underneath that is the one worth carrying. Nearly a third of the tested prenatals came in below acceptable thresholds on folic acid or folate, one of the most firmly established interventions in preventive medicine. One A Day Prenatal Multi Gummy contained 28% of its labeled folic acid.
Bird&Be announced $13 million on September 22, co-led by BDC Thrive and BFG Partners, with BAM Ventures, Founder Collective, Rejuvenation Ventures and HSR Ventures participating. Co-founders Samantha Diamond, the CEO, and Breanna Hughes built the business around treating male factor as half of infertility rather than an afterthought. Company-reported figures include eight-figure revenue within three years, roughly 100% year over year growth, 75% of revenue from subscriptions, and a clinician referral channel up 200% that now supplies about one in ten new customers. PR Newswire
Supplements are a category with almost no enforcement of the one thing they sell, which is dose. In that environment, delivering what the label promises becomes a defensible asset, and the referral growth is the market registering it: physicians route patients toward the product they can defend in a consultation.
A moat built on regulatory absence is worth more in a weakly policed category than in a tightly policed one.
Decision question: what is the basic promise everyone in our category makes and almost nobody verifies, and what would it cost us to be the one that does?
Sources: Telix and ITM · BioSpace · STAT · Bio-Techne · Bird&Be · Consumer Reports
The AI Operating Model
The VA bought eleven months of evidence, then refused to be locked in.
The Department of Veterans Affairs has placed Abridge and Knowtex on its Ambient Scribe Enterprise contract, a multi-award indefinite-delivery, indefinite-quantity vehicle with a ceiling of $775.72 million over five years, reported September 22. Both had been running in VA facilities since an October 2025 pilot. The technology now operates at more than 75 VA medical centers across primary care, behavioral health, physical medicine and rehabilitation, and medical and surgical specialties. Nextgov/FCW · CDO Magazine
Three features of this award matter more than the dollar figure.
It was bought on operating history. The pilot ran nearly a year before the enterprise vehicle was awarded. Dr. Rebecca Gladding, acting deputy chief of psychiatry at VA Greater Los Angeles, reports more than 986,000 VA primary care appointments have used ambient scribes since October 2025, with veterans declining the technology less than 1% of the time. Patient refusal is the failure mode nobody models in a pilot deck, and under 1% across nearly a million encounters is a real finding.
The structure preserves competition. A multi-award IDIQ means the two vendors compete for individual task orders rather than one owning the enterprise, and the VA can shift work between them without renegotiating. For an agency deploying clinical AI across hundreds of facilities, that is a deliberate hedge against both vendor lock-in and technology risk, and it is the part most private health systems have not copied.
Both the incumbent and the challenger made it. Abridge is the best-capitalized name in ambient documentation, and CEO Shiv Rao points to being the only vendor integrating with both legacy and new VA electronic health records at scale. Knowtex is far smaller, founded by Caroline Zhang, its CEO, and Jocelyn Kang, its CTO, both Stanford AI researchers, backed by Y Combinator, HF0 and Stanford StartX Med. Knowtex reports 79 VA medical centers, roughly 7,000 clinicians and 88% sustained adoption; those figures are company-reported and not independently confirmed. Knowtex
The buyer did not choose between them. It kept both and made them compete, which tells you what it thinks it is purchasing.
Worth naming for this readership: two women out of a Y Combinator batch now sit alongside the category leader on one of the largest healthcare AI vehicles the federal government has issued. The route ran through a buyer whose evaluation rested on demonstrated operation inside its own hospitals. That is a path to scale most founders here have written off.
Decision question: for the clinical technology we have deployed, what is our sustained utilization at twelve months, what is our patient refusal rate, and would we put either number in a contract?
Sources: Nextgov/FCW · CDO Magazine · Knowtex
The Regulatory Inflection
A coverage rule, not a clearance, is what repriced cervical screening this week.
Teal Health announced a $22 million Series A on September 22, led by .406 Ventures, with Emerson Collective, Forerunner, Labcorp, Serena Ventures and MPower Partners participating, bringing total funding to $45 million. Co-founder and CEO Kara Egan sells the Teal Wand, an at-home cervical cancer screening kit authorized by the FDA in 2025 that pairs self-collection with a telehealth visit and referral into follow-up care. It costs $99 with insurance and $249 in cash. Teal Health
The FDA authorization happened last year. The financing happened this week, and the gap between those dates is the point.
What changed is the expected coverage position. Following a federal recommendation, most health plans are anticipated to be required to cover self-collected HPV tests without patient cost sharing from 2027. Those requirements are not yet fully in force, so this is an expectation rather than a guarantee. But a company selling a $99 test into a market where that test is expected to become free at the point of care is not raising to create demand. It is raising to be in position when demand is created by rule. Fierce Healthcare
Clearance is the permission layer. Coverage is the demand layer. They rarely arrive together, and the second is usually worth more.
One caution on Teal’s own numbers. The company reports that roughly two thirds of its users were behind on screening intervals, and that it detects cervical cancer at about five times the rate general population screening would predict. The first is a genuine access finding. The second is company-reported and structurally expected: a product that preferentially reaches under-screened women will find more disease per test than one screening women who arrive on schedule.
Why this matters for TUC: nearly every screening, diagnostic and preventive asset in this industry has a coverage date attached to it somewhere, published and knowable, and most cap tables have not priced it. Women’s health is unusually exposed, because so much of it sits in preventive services, which is exactly where coverage requirements land.
Decision question: for the asset we own or advise, what is the next scheduled coverage decision that touches it, and are we positioned before that date or after it?
Sources: Teal Health · Fierce Healthcare · MobiHealthNews
Career, Board & Capital
Career: the operating disciplines are appreciating faster than the creative ones.
Manufacturing and quality. Supply chain. Regulatory CMC. Deployment and adoption engineering. Market access. Each has spent a decade being described as a cost center, and each decided a transaction this week.
A record built on generating ideas competes in an abundant market. A record built on things delivered at scale competes in a scarce one. So say it with the number attached. Not “I led market access,” but “I won coverage for a category that had none, and here is what it did to revenue.”
Board: ask where the chain breaks.
Walk any asset from invention to patient and name who controls each link: who manufactures it, who supplies the manufacturer, who pays for it, who has to change a workflow for it to be used. Then mark which links you own and which you rent.
The sharper version makes a good board question: which single external party could shut down our growth plan without ever touching our technology? Telix answered by buying the link. Merck answered by buying the input. A board that has never asked is carrying a concentration risk nobody has named.
Capital: the multiple appears to be moving toward the constraint.
The two largest transactions this week were both for infrastructure, which suggests buyers are paying for reliability of supply and delivery rather than novelty of discovery. A chokepoint, whether isotope production, a reagent line, a payer position or a deployment record, may carry pricing power that a differentiated molecule increasingly does not, because the molecule now faces computational competition and the chokepoint does not.
Hold that loosely, because the public tape is about to test it. Iambic Therapeutics filed its S-1 on September 21 for a Nasdaq Global Select listing under the ticker IAM, reporting a net loss of $50.1 million for the six months to June 30, 2026 and $207.9 million in cash. Its lead asset IAM1363, a HER2 inhibitor, is in Phase 1/1b. NVIDIA, Catalio and Coatue are among the principal stockholders. SEC S-1
If it prices well, the market still pays a premium for discovery and this week’s pattern is narrower than it looks. If it struggles, the reading above gets stronger.
Diligence question: what does this company control that a well-funded competitor could not replicate in eighteen months, and is it an idea or an asset?
What Boards Are Quietly Discussing
If our single most important supplier failed an inspection next quarter, how long would it take us to find out, and how long after that until it reached our revenue?
Most boards can answer the first part and almost none can answer the second. ITM’s inspection finding became a complete response letter, then a valuation event, then an acquisition, inside a few months. Supply and quality risk now reaches the income statement faster than most governance calendars are built to catch, and companies that discover this during a transaction rather than before one tend to be the sellers.
The Syndicate Desk
Biweekly diligence sessions continue this month.
Two screens follow from this week. The first is companies that own a chokepoint rather than a product: a manufacturing capability, a supply relationship, a deployment footprint, or a coverage position a better-funded competitor could not buy quickly. The second is companies positioned in front of a dated, public reimbursement change, where the catalyst is knowable and the timing is not a matter of opinion.
Send what you are seeing to hello@theuplyftcollective.com: company name, stage, raise size, one sentence on why the return case could be real, and one sentence on why you trust the founder, category, evidence, or timing. Nothing shared constitutes a commitment, and confidential information should not be circulated without permission.
The Uplyft Lens: Three Moves for This Month
1. This week: draw your chain and mark what you rent.
Write out every link between your primary asset and the patient, naming who controls each one, then circle the links you do not own. It takes twenty minutes, and it is the same analysis Telix and Merck each just paid billions to act on.
2. By mid-October: find your coverage date.
Identify the next scheduled reimbursement or coverage decision touching your product or portfolio and write down the date. If you have one and have not priced it, that is this month’s highest-return homework. If there genuinely is none, that absence is worth understanding.
3. By month-end: instrument one adoption number.
Measure sustained utilization at twelve months rather than at launch. The VA committed to a vehicle worth up to $775.72 million only after watching two vendors operate in its own hospitals for eleven months. Whatever your number is, knowing it puts you ahead of most of the people you will negotiate with.
The industry spent a decade paying for the idea. This week it paid for the plant, the reagent, the deployment record and the dose on the label. If that holds, the next repricing will begin somewhere this industry has never spent much time looking.
The Uplyft Collective is a private leadership ecosystem for architects of strategy in healthcare, pharma, biotech, medtech, and life sciences. Take your seat at the table.
